Across its top 16 institutional holders, SBEV's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 11/100, avg. turnover score 34/100).
Quarterly Activity
Recent Activity
+$196.6K
Total Buy Value
$61.4K
Total Sell Value
New buy4
Trim3
Add4
Sold out3
8
Net Buyers
6
Net Sellers
Smart Money Convergence
SBEV does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
7
Filings (14d)
Data as of 2026-07-16
2026-07-16
Splash Beverage Group (SBEV) announced a 1-for-4 reverse stock split, effective July 24, 2026, and concurrently reduced its authorized shares from 400 million to 100 million. Trading was halted by the NYSE American on July 16 because the stock fell below $0.10 per share (last trade at $0.0936). Trading is expected to resume on a split-adjusted basis on July 27, 2026.
Splash Beverage Group (ticker SBEV) issued a press release on July 14, 2026, announcing recent settlement agreements to resolve certain liabilities and improve its balance sheet, along with a 1-for-4 reverse stock split. The press release is attached as an exhibit to this 8-K filing.
Splash Beverage Group reached a settlement with lender Decathlon Alpha IV, L.P. on a loan originally taken in December 2020. The company will pay just $301,800.55 to clear the entire remaining balance of $2.83 million by the end of August. Once paid, the lender will permanently release Splash from all obligations under the loan agreement.
Splash Beverage Group (SBEV) has secured exclusive worldwide rights to develop and commercialize CannEpil®, a cannabinoid-based drug for epilepsy and seizure disorders, through a licensing agreement with Argent Biopharma. The deal includes a 15% royalty on net sales, development milestones requiring clinical trials and FDA filing within set timelines, and an initial term of 20 years. In connection, the company is issuing $5.5 million in preferred stock to cancel existing notes and has secured a $1 million investment commitment from its equity line provider to support commercialization.
Who are the top institutional investors holding SPLASH BEVERAGE GROUP INC (SBEV)?
Major stakeholders currently include Hrt Financial LP ($48.0K), Virtu Financial LLC ($36.0K), Summit Trail Advisors, LLC ($35.9K). Based on the latest 13F filings, there are a total of 16 tracked investment funds and institutions maintaining positions in SBEV.
What is the overall institutional sentiment toward SBEV recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $93.2K, driven by 8 managers accumulating shares while 6 reduced their exposure.
Which institutions have been selling or reducing their SBEV positions?
In the latest period, 3 funds trimmed their holdings, and 3 managers completely exited their positions. The aggregate reported sell value was $61.4K.
Are there any notable investors adding SBEV to their portfolios?
Yes, buying activity remains notable. 4 institutions opened new positions in {ticker}, and 4 existing holders added to their shares. The total reported buy value for the quarter amounted to $196.6K.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter